Evidence map›Paper›PMID 26157433›Full record

ArticleFrontiers in microbiology2015

Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins.

James W Gillespie, Amanda L Gross, Anatoliy T Puzyrev, Deepa Bedi, Valery A Petrenko

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Ligand-targeted theranostic nanomedicines against cancer.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  8. Promiscuous tumor targeting phage proteins.Protein engineering, design & selection : PEDS · 2016
    Article
  9. Selection of Lung Cancer-Specific Landscape Phage for Targeted Drug Delivery.Combinatorial chemistry & high throughput screening · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

James W GillespieDepartment of Pathobiology, College of Veterinary Medicine, Auburn University Auburn, AL, USA.
Amanda L GrossDepartment of Pathobiology, College of Veterinary Medicine, Auburn University Auburn, AL, USA.
Anatoliy T PuzyrevDepartment of Pathobiology, College of Veterinary Medicine, Auburn University Auburn, AL, USA.
Deepa BediDepartment of Pathobiology, College of Veterinary Medicine, Auburn University Auburn, AL, USA.
Valery A PetrenkoDepartment of Pathobiology, College of Veterinary Medicine, Auburn University Auburn, AL, USA.
Auburn University · US

Funding

Physico-Chemical Nanocharacterization CoreU54CA151881 · NCI · NORTHEASTERN UNIVERSITY · PI TORCHILIN, VLADIMIR P · 2010 to 2014
$12.4M
NCI NIH HHS U54 CA151881
6 · The paper itself

Abstract

Active tumor targeting of nanomedicines has recently shown significant improvements in the therapeutic activity of currently existing drug delivery systems, such as liposomal doxorubicin (Doxil/Caelyx/Lipodox). Previously, we have shown that isolated pVIII major coat proteins of the fd-tet filamentous phage vector, containing cancer cell-specific peptide fusions at their N-terminus, can be used as active targeting ligands in a liposomal doxorubicin delivery system in vitro and in vivo. Here, we show a novel major coat protein isolation procedure in 2-propanol that allows spontaneous incorporation of the hydrophobic protein core into preformed liposomal doxorubicin with minimal damage or drug loss while still retaining the targeting ligand exposed for cell-specific targeting. Using a panel of 12 structurally unique ligands with specificity toward breast, lung, and/or pancreatic cancer, we showed the feasibility of pVIII major coat proteins to significantly increase the throughput of targeting ligand screening in a common nanomedicine core. Phage protein-modified Lipodox samples showed an average doxorubicin recovery of 82.8% across all samples with 100% of protein incorporation in the correct orientation (N-terminus exposed). Following cytotoxicity screening in a doxorubicin-sensitive breast cancer line (MCF-7), three major groups of ligands were identified. Ligands showing the most improved cytotoxicity included: DMPGTVLP, ANGRPSMT, VNGRAEAP, and ANDVYLD showing a 25-fold improvement (p < 0.05) in toxicity. Similarly DGQYLGSQ, ETYNQPYL, and GSSEQLYL ligands with specificity toward a doxorubicin-insensitive pancreatic cancer line (PANC-1) showed significant increases in toxicity (2-fold; p < 0.05). Thus, we demonstrated proof-of-concept that pVIII major coat proteins can be screened in significantly higher throughput to identify novel ligands displaying improved therapeutic activity in a desired cancer phenotype.

Indexed as

breast cancerdoxorubicinliposomal drug deliverypancreatic cancerphage displaytargeted nanomedicines

Identifiers

PMID26157433
PMCPMC4477153
OpenAlexW1519262706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.